- Market Realist•6 hours ago
BioMarin's application for cerliponase alfa, an enzyme replacement therapy, is under review by the FDA for the treatment of CLN2 disease.
- Market Realist•7 hours ago
BioMarin Pharmaceutical (BMRN) expects its existing commercialized drugs to add $1.1 billion and $1.2 billion to its top line in 2016.
- Market Realist•10 hours ago
BioMarin Pharmaceutical (BMRN) is a high growth company that primarily focuses on rare diseases. In this series, we’ll discuss the pillars for its success.
BioMarin Pharmaceutical Inc. (BMRN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||94.80 x 100|
|Ask||98.48 x 100|
|Day's Range||94.25 - 97.19|
|52wk Range||62.12 - 118.48|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-29.53|
|Avg Vol (3m)||1,805,282|
|Dividend & Yield||N/A (N/A)|